James P. Allison received the 2014 Szent-Györgi Prize for Progress in Cancer Research.
- Author:
Jie ZHAO
1
;
Peter SCULLY
;
Sujuan BA
Author Information
- Publication Type:Journal Article
- MeSH: Awards and Prizes; Humans; Immunotherapy; Melanoma; Neoplasms; United States
- From:Chinese Journal of Cancer 2014;33(9):416-420
- CountryChina
- Language:English
- Abstract: The Szent-Györgyi Prize for Progress in Cancer Research is a prestigious scientific award established by the National Foundation for Cancer Research (NFCR) -- a leading cancer research charitable organization in the United States that is committed to supporting innovative cancer research on the global scale that aims to cure cancer. Each year, the Szent-Györgyi Prize honors an outstanding researcher whose original discoveries have expanded our understanding of cancer and resulted in notable advances in cancer prevention, diagnosis, or treatment. The prize also promotes public awareness of the importance of basic cancer research and encourages the sustained investment needed to accelerate the translation of these research discoveries into new cancer treatments. This report highlights the history and mission of the Szent-Györgyi Prize, its role in promoting discovery-oriented cancer research, and the pioneering work led by the 2014 prize winner, Dr. James Allison. Dr. Allison's work in the area of cancer immunotherapy led to the successful development of immune checkpoint therapy, and the first drug approved by the United States Food and Drug Administration for the treatment of metastatic melanoma.
